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Abstract
Background: Bacterial pneumonia is a well described complication of influenza. In recent years, community-onset
methicillin-resistant Staphylococcus aureus (cMRSA) infection has emerged as a contributor to morbidity and mortality in
patients with influenza. Since the emergence and rapid dissemination of pandemic A(H1N1)2009 influenzavirus in April
2009, initial descriptions of the clinical features of patients hospitalized with pneumonia have contained few details of
patients with bacterial co-infection.
Methodology/Principal Findings: Patients with community–acquired pneumonia (CAP) caused by co-infection with
pandemic A(H1N1)2009 influenzavirus and cMRSA were prospectively identified at two tertiary hospitals in one Australian
city during July to September 2009, the period of intense influenza activity in our region. Detailed characterization of the
cMRSA isolates was performed. 252 patients with pandemic A(H1N1)2009 influenzavirus infection were admitted at the two
sites during the period of study. Three cases of CAP due to pandemic A(H1N1)2009/cMRSA co-infection were identified. The
clinical features of these patients were typical of those with S. aureus co-infection or sequential infection following influenza.
The 3 patients received appropriate empiric therapy for influenza, but inappropriate empiric therapy for cMRSA infection; all
3 survived. In addition, 2 fatal cases of CAP caused by pandemic A(H1N1)2009/cMRSA co-infection were identified on post–
mortem examination. The cMRSA infections were caused by three different cMRSA clones, only one of which contained
genes for Panton-Valentine Leukocidin (PVL).
Conclusions/Significance: Clinicians managing patients with pandemic A(H1N1)2009 influenzavirus infection should be
alert to the possibility of co-infection or sequential infection with virulent, antimicrobial-resistant bacterial pathogens such
as cMRSA. PVL toxin is not necessary for the development of cMRSA pneumonia in the setting of pandemic A( H1N1) 2009
influenzavirus co-infection.
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Introduction
Influenza is an important cause of morbidity and mortality [1].
Bacterial co-infection is an important contributor to morbidity and
mortality during influenza pandemics [2,3] and during periods of
seasonal influenza activity in inter-pandemic periods [4]. In
particular, Staphylococcus aureus pneumonia is a well-described life-
threatening complication of pandemic [5,6] and seasonal [7–10]
influenza. Following the recent worldwide emergence of commu-
nity-onset methicillin-resistant S. aureus (cMRSA), several reports
have described severe co-infection with seasonal influenzavirus
and cMRSA [7–12]. Severe necrotizing S. aureus pneumonia in
previously healthy individuals (often with a preceding history of
influenza-like illness[ILI]) has been associated with the synergo-
hymenotrophic exotoxin Panton-Valentine Leukocidin (PVL) [11–
13], and the genes encoding PVL are present in many cMRSA
clones, including ST8-MRSA-IV/USA300 in the United States
[14], ST59-MRSA-VT in Eastern Asia [15], ST80-MRSA-IV in
Europe [16], and ST93-MRSA-IV and ST30-MRSA-IV in
Australia [17].
In April 2009 pandemic A(H1N1)2009 influenzavirus emerged
in North America and rapidly disseminated worldwide. First
identified in Australia on May 12 2009, this virus was the
dominant circulating influenza strain through the Australian
winter; as of October 16, over 37 000 laboratory-confirmed cases
of pandemic A(H1N1)2009 influenzavirus infection had been
recorded, resulting in nearly 5 000 hospitalizations and 186 deaths
[18]. Early reports suggested that pandemic A(H1N1)2009
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infection in that it spared older individuals, whilst moderate/
severe infection was relatively common in younger patients[19,20].
This pattern was also seen in Australia and was associated with
significant utilization of ICU resources [21].
This report describes the features of severe pneumonia caused
by pandemic A(H1N1)2009 influenzavirus/cMRSA co-infection
in Western Australia, where cMRSA has been endemic for .15
years [17].
Materials and Methods
Case Identification
Patients hospitalized with laboratory–confirmed pandemic
A(H1N1)2009 influenzavirus infection between July and Septem-
ber 2009 were prospectively identified at two adult teaching
hospitals in Perth, Western Australia (Royal Perth Hospital [850
beds] and Sir Charles Gairdner Hospital [650 beds]). From this
data, patients with community-acquired pneumonia (CAP) caused
by co-infection with pandemic A(H1N1)2009 influenzavirus and
MRSA were identified. In addition, cases of pandemic
A(H1N1)2009 influenzavirus/MRSA co-infection identified at
post-mortem examination performed at the State Forensic
Pathology service during the same period were identified. Clinical
information was obtained by chart review and for deceased
patients, from general practitioners and/or paramedical staff. As
this study was considered to be audit or ‘low risk’ research activity
according to institutional and National Health and Medical
Research Council criteria [22,23], formal ethics committee
approval and informed consent from the patients/next of kin
were not required.
Definitions
Community-acquired pneumonia was diagnosed if the patient
had not been hospitalized within the preceding 3 months and had
either a) symptoms and/or signs of lower respiratory tract infection
together with pulmonary consolidation or infiltrates on imaging, or
b) both macroscopic and microscopic evidence of pneumonia on
post-mortem examination. Pandemic A(H1N1)2009 influenzavirus
infection was diagnosed if the patient had symptoms or signs of an
ILI and returned a positive result for pandemic A(H1N1)2009
influenzavirus RNA by polymerase chain reaction (PCR) on a
respiratory tract specimen. Community-onset MRSA (cMRSA)
infection was diagnosed if the patient returned a positive culture
result for MRSA from blood cultures and/or from a lower
respiratory tract specimen ,48h following admission; patients
from long-term care facilities were also included.
MRSA Identification and Characterization
MRSA was isolated and identified from clinical specimens using
routine laboratory methods. Cefoxitin, penicillin, clindamycin,
erythromycin, tetracycline, trimethoprim, ciprofloxacin, gentami-
cin, rifampin, fusidic acid and mupirocin susceptibility testing was
performed by disk diffusion according to Clinical and Laboratory
Standards Institute (CLSI) recommendations [24]. CLSI interpre-
tive criteria [25] were used for all antimicrobials except fusidic acid
[26] and mupirocin [27]. Cefoxitin resistance was confirmed by
the detection of the mecA gene by PCR [28]. Susceptibility testing
for vancomycin and linezolid was performed by Etest (AB Biodisk,
Solna, Sweden) and results interpreted according to CLSI
breakpoints [29]. Pulsed-field gel electrophoresis (PFGE) of
chromosomal DNA following Sma1 enzyme restriction was
performed as previously described [30] using the CHEF DR III
System (Bio-Rad Laboratories Pty Ltd). Patterns were examined
visually, scanned with a Quantity One device (Bio-Rad Labora-
tories Pty Ltd), digitally analyzed using FPQuest (Bio-Rad
Laboratories), and grouped according to the criteria of Tenover
et al. [31]. Chromosomal DNA for multilocus sequence typing
(MLST) and spa typing was prepared using the DNeasy Tissue kit
(Qiagen Pty Ltd). MLST was performed as previously described
[32]; sequences were compared with those on the MLST website
to assign a sequence type (ST) (http://saureus.mlst.net/). Spa
typing was performed as previously described [33] and spa types
assigned as per standard methodology (http://spa.ridom.de/).
The SCCmec element was typed by multiplex PCR [34]. Detection
of the PVL genes (lukS-PV and lukF-PV) was performed by PCR as
previously described [35]. Finally, gene profiling using a S. aureus
specific DNA microarray was performed using the CLONDIAG
platform; protocols, data interpretation and evaluation procedures
for the oligonucleotide array hybridizations were performed as
previously described [36,37].
Detection of Pandemic A(H1N1)2009 Influenzavirus
Testing of respiratory tract specimens for influenzavirus was
performed on request; in addition, one centre routinely tested
lower respiratory tract specimens from hospitalized patients that
were submitted for bacterial culture during July–September 2009.
Upper respiratory tract specimens included nose and throat swabs
collected using either plastic-shafted Dacron swabs placed into
viral transport medium (VTM) or cotton-tipped wire swabs that
were vortexed in VTM in the laboratory. Lower respiratory tract
specimens included expectorated sputum, sputum aspirated via an
endotracheal tube, bronchoalveolar lavage fluid and lung sections
obtained at post-mortem examination.
Three duplex real-time reverse transcriptase-PCR assays were
run on each specimen to detect matrix gene targets specific for
influenza A and influenza B, hemaaglutinin gene targets specific
for influenza A subtypes H1 (seasonal), H1 (pandemic) and H3,
and MS2 RNA coliphage (MS2) to monitor the efficiency of the
assay [S. Williams, G. Chidlow, D.W. Smith, manuscript
submitted]. Briefly, nucleic acid was extracted from 200 mL
sample volume, and a standardized amount of MS2 was added to
the specimen to monitor sample extraction efficiency, the removal
of reverse transcription and PCR inhibitors and the cDNA
production process [38]. Primers and probes [listed in Table S1]
were designed using Primer Express software (Applied Biosystems,
USA) with the exception of those for the influenza A matrix gene
[39]; primers and probes to detect regions of the haemagglutinin
gene that differentiated the pandemic A(H1N1)2009 from seasonal
strains were designed based on sequence information obtained
from the Global Initiative on Sharing Avian Influenza data
(GISAID) (http://platform.gisaid.org/). DNA amplification was
performed in real-time thermocyclers (RotorgeneQ, Qiagen,
Germany); reactions with cycling threshold values ,37 were
reported as reactive. Negative samples that showed inhibition in
the MS2 PCR were diluted 1:5 and repeated. An evaluation of the
pandemic A(H1N1)2009 PCR showed that it detected approxi-
mately 100 TCID50/mL at a 95% confidence level, with a
diagnostic sensitivity of 98.8% and a specificity of 100% [S.
Williams, G. Chidlow , D.W.Smith, manuscript submitted].
Examination of Lung Specimens from Fatal Cases
When macroscopically abnormal lungs were observed at post-
mortem examinations, samples of lung tissue were obtained and
submitted for histopathological examination, bacterial and fungal
microscopy and culture, and detection of respiratory tract
pathogens by PCR.
cMRSA/Pandemic Influenza
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252 patients with pandemic A(H1N1)2009 influenzavirus
infection were admitted to the two participating hospitals during
the 3-month period of study (149 to Royal Perth Hospital and and
103 to Sir Charels Gairdner Hospital). From these cases, 3 cases of
co-infection with pandemic A(H1N1)2009 influenzavirus/cMRSA
co-infection were identified (1.2% of all admissions with pandemic
A(H1N1)2009 influenzavirus). In addition, 2 cases of pandemic
A(H1N1)2009 influenzavirus/cMRSA co-infection were identified
at post-mortem examination during the same time period.
Clinical Details
The clinical characteristics of the cases of cMRSA/pandemic
A(H1N1)2009 influenzavirus co-infection are summarized in
table 1. There were 3 female and 2 males, aged between 34 and
79 years. Three cases (patients 1–3) were diagnosed following
hospital presentation and two (patients 4 and 5), who died at
home, were diagnosed following post-mortem examination. Two
patients lived at the same long-term care facility, whilst the other
patients lived independently in the community. Four of the 5
patients had conditions that may have increased their risk of
pneumonia, including quadriplegia (two patients) asthma (one
patient), cirrhosis (one patient) and diabetes mellitus (one patient).
Two of the 5 cases (patients 3 and 4) had known MRSA infection/
colonization prior to the onset of their illness (with the same
cMRSA clone that subsequently caused their co-infection).
The three patients that presented to hospital required
admission, with hospital length of stay ranging from 9–46 days.
All three patients had ILI prior to presentation (duration from 3–5
days), and all had clinical and imaging features of pneumonia at
presentation (see figures 1 and 2 for representative imaging) with
Pneumonia Severity Index (PSI) score ranging from 74 (class II) to
113 (class IV). One patient (patient 1, PSI score=73) required
intensive care unit admission for mechanical ventilation on day 8
of admission, and another patient (patient 3) received bi-level
positive airways pressure (BiPAP) ventilation on a respiratory
ward.
Patients 4 and 5 died at home not having presented for medical
assessment. Patient 4 was noted to have an ILI when visited by
domiciliary nurses three days prior to death; when contacted by a
primary care practitioner on the day of death, the patient was
confused and dyspnoiec, and subsequently suffered cardiorespira-
tory arrest when paramedics attended shortly afterwards. Post-
mortem examination findings included acute pulmonary oedema,
right lower lobe consolidation, and moderate coronary artery
disease; the cause of death was recorded as acute pneumonia.
Patient 5 had complained to a relative of being generally unwell
with right-sided abdominal pain 3 days before they were found
deceased; post-mortem examination demonstrated right middle
lobe pneumonia, with previously undiagnosed disseminated small
cell carcinoma with hepatic metastases, and moderate to severe
coronary artery disease with cardiomegaly; the cause of death was
recorded as acute pneumonia.
Microbiology Results
The three patients who presented to hospital had pandemic
A(H1N1)2009 influenzavirus detected by PCR in upper and/or
lower respiratory tract specimens. Two patients (patient 1 and
patient 2) had nose and throat swabs taken at admission that tested
negative for pandemic A(H1N1)2009 influenzavirus; however both
patients had positive results on lower respiratory tract specimens
(patient 1 from sputum aspirated from the endotracheal tube on
day 8 of admission, and patient 2 on expectorated sputum
obtained day 1 of admission). Two patients (patients 1 and 3) had
surveillance specimens obtained after commencement of therapy;
patients 1 remained positive for pandemic A(H1N1)2009 influen-
zavirus RNA by PCR on endotracheal sputum on day 16 of
admission (following two 5-day courses of oseltamivir), whereas
patient 3 was negative on repeat nose/throat swab on day 7 of
admission (whilst still receiving oseltamivir). The two cases
identified at post-mortem examination had pandemic
A(H1N1)2009 influenzavirus RNA detected on tissue samples
from macroscopically abnormal lung; no other viral pathogens
were identified. In addition, patient 1 had a .4 fold rise in
influenza A antibody titre on specimens collected on the day of
admission and day 8 of admission.
The three patients who presented to hospital all had MRSA
cultured from blood and from expectorated sputum specimens
collected within 12h of admission. Two of these patients (patients 2
and 3) had negative surveillance blood cultures 72–96h after
admission; the remaining patient (patient 1) did not have
surveillance blood cultures performed until day 26 of admission
(which were negative), but was culture-positive for MRSA on a
pleural fluid specimen obtained 11 days after the commencement
of MRSA therapy. The two post-mortem cases had Gram-positive
cocci resembling staphylococci present on Gram’s stain of tissue
submitted to the microbiology laboratory, and cultured MRSA
from lung specimens; one patient also cultured methicillin-
susceptible S. aureus and E. coli but these organisms were present
in relatively low numbers on culture.
Histopathology
Histopathological examination of lung obtained from patients 4
and 5 demonstrated features of acute and/or necrotizing
pneumonia (figures 3 and 4).
Treatment of Pandemic A(H1N1)2009 Infection
The three patients who presented to hospital received empiric
therapy for pandemic A(H1N1)2009 influenzavirus infection with
oseltamivir, at doses of 75mg bid or 150mg bid, for durations of
between 5 and 10 days. Patient 1 initially received 5 days of
oseltamivir, which was ceased when nose/throat swabs returned
negative results; following receipt of positive results for pandemic
A(H1N1)2009 influenzavirus on sputum on day 8 of admission,
oseltamivir was re-introduced at the same dose and continued for
another 5 days.
Treatment of cMRSA Infection
None of the patients received empiric antimicrobial therapy that
would be considered appropriate for bacteraemic cMRSA
pneumonia (including patient 3, who had a past history of MRSA
infection). All 3 patients received vancomycin following receipt of
positive blood culture results or sputum microscopy with gram-
positive cocci resembling staphylococci in Gram’s stain (empiric
therapy with vancomycin in combination with an antistaphylo-
coccal b-lactam such as flucloxacillin is standard therapy for
suspected community-acquired S. aureus sepsis in our region).
Duration of MRSA therapy ranged from 14 to 76 days; patient 1
received combination therapy with vancomycin and clindamycin
for 7 days, followed by linezolid (IV then PO) for 39 days, followed
by oral clindamycin on discharge to complete a further 4 weeks of
therapy; patient 2 received vancomycin monotherapy for 14 days
(5 as an outpatient), and patient 3 received 7 days of vancomycin
and oral linezolid; vancomycin was ceased after 7 days because of
neutropenia and treatment was continued with oral linezolid to
complete a total of 14 days of therapy.
cMRSA/Pandemic Influenza
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All patients who survived until hospital presentation were
discharged without permanent sequelae.
MRSA Typing Results
Three different cMRSA clones were identified in 5 patients
(Table 2 and Figure 5). These cMRSA clones (ST1-MRSA-IV,
ST93-MRSA-IV and ST78-MRSA-IV) are all known to circulate
in the Western Australian community [17]. Only the isolate from
patient 1 (ST93-MRSA-IV) contained the PVL toxin genes lukS-
PV/lukF-PV; this patient had a severe and protracted clinical
course consistent with necrotizing pneumonitis, which was
supported by imaging findings (figure 3). Patients 2 and 3, who
resided at the same long-term care facility, had MRSA isolates that
were indistinguishable by MLST (ST1-MRSA-IV) but had
different PFGE patterns (3-band difference) and different spa
types. Patients 4 and 5 had ST78-MRSA-IV isolated from lung
tissue (indistinguishable PFGE, spa type t186) however there was
no known epidemiological connection between these two cases.
Results of DNA microarray experiments on MRSA isolated
from the cases were 100% concordant with PCR results for lukS-
PV/lukF-PV and sequencing results for MLST. All of the MRSA
isolates were agr group III; none contained the arginine catabolic
mobile element (ACME) locus. All isolates contained the genes for
delta-haemolysin (hld), putative haemolysin III (hIII), staphyloki-
nase (Sak), and staphylococcal complement inhibitor (Scn); genes
for alpha-haemolysin (hla), beta-haemolysin (hlb), gamma-haemo-
lysin (lukF and lukS), putative haemolysins hlIII and leukocidin
genes lukD/E were present in the four lukS-PV/lukF-PV-negative
isolates. Enterotoxin genes were detected in three isolates (entA,
entH, entK and entQ in isolates from patient 2, entA and entH in
isolates from patient 3 and entC and entL in isolates from patient 5).
Genes encoding the following microbial surface components
recognizing adhesive matrix molecules (MSCRAMMS) were
detected in all isolates: bone sialoprotein-binding protein (bbp),
clumping factors A (clfA) and B (clfB), cell-wall associated
fibronectin binding protein (ebh), cell surface elastin-binging
protein (ebpS), enolase (eno), fibrinogen-binding protein (fib),
fibronectin binding proteins A (fnbA) and B (fnbB), Serine-aspartate
rich fibrinogen binding proteins C(sdrC) and D(sdrD), and von
Willebrand Factor binding protein (vwb). Complete results of the
DNA microarray experiments are presented in table S2, and the
raw data is available from the authors on request.
Discussion
Initial descriptions of severe pandemic A(H1N1)2009 influen-
zavirus infection reported from the United States were charac-
teristic of a viral pneumonitis, with bacterial co-infection or
sequential infection being relatively uncommon [19,20]. In
particular, MRSA co-infection occurred in only 1/272 patients
hospitalized with pandemic A(H1N1)2009 influenzavirus infec-
tion reported to the US Centers for Disease Control between
April and June 2009 [20]. As the pandemic has progressed,
evidence has emerged that bacterial infection occurs in some
patients, although the exact incidence and contribution to
morbidity and mortality has yet to be determined. Post-mortem
lung specimens from 77 cases of fatal A(H1N1)2009 influenza-
Figure 2. Chest computerized tomography scan in pandemic A(H1N1)2009/cMRSA co-infection. Patient 1, (a) 8 days and (b) 27 days
following admission.
doi:10.1371/journal.pone.0008705.g002
Figure 1. Chest radiography in pandemic A(H1N1)2009/cMRSA co-infection. (a) patient 1, (b) patient 3.
doi:10.1371/journal.pone.0008705.g001
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chemical and/or molecular evidence of concurrent bacterial
infection in 22 (29%); 7 had S. aureus identified, 5 of which were
MRSA [40]. As minimal clinical information was provided in this
report, it is not known whether appropriate empiric antimicrobial
therapy was given to these patients, although 4 had received
antibacterial and antiviral therapy. In addition, a recent report
described a case of fatal cMRSA/pandemic A(H1N1)2009
influenzavirus infection in a previously well 42-year-old male
who died within 48h of admission [41]; this patient did not
receive antiviral therapy, but did receive vancomycin and
clindamycin.
The clinical features of pandemic A(H1N1)2009 influenzavirus/
cMRSA co-infection appear similar to those described previously
with seasonal influenzavirus/cMRSA co-infection [7–12]. All
patients described an ILI prior to presentation/death, and the
three patients who presented to hospital had moderately severe
CAP and MRSA bacteremia. Pandemic A(H1N1)2009 influenza-
virus RNA was not detected on nose/throat swabs in 2 of these
three cases, but was detected on lower respiratory tract samples.
We therefore recommend that in addition to upper respiratory
tract specimens, lower respiratory tract specimens should be tested
for pandemic A(H1N1)2009 influenzavirus if the patient has
pneumonia.
Figure 4. Histopathology of pandemic A(H1N1)/cMRSA co-infection. Patient 4, right lower lobe lung, demonstrating acute pneumonia
(haematoxylin and eosin, 6200).
doi:10.1371/journal.pone.0008705.g004
Figure 3. Histopathology of pandemic A(H1N1)/cMRSA co-infection. Patient 5, right lower lobe lung, demonstrating areas of necrotizing
pneumonia (haematoxylin and eosin, 640).
doi:10.1371/journal.pone.0008705.g003
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virus/cMRSA co-infection who were admitted to hospital received
empiric therapy with oseltamivir, however none received empiric
therapy considered appropriate for invasive cMRSA infection.
This was in spite of the fact that two of these patients were known
to be colonized with MRSA prior to developing pneumonia. The
small number of patients in this report makes it impossible to draw
any conclusions regarding the impact of appropriate empiric
therapy for either pandemic A(H1N1)2009 influenzavirus or for
cMRSA.
Only one of the 5 cases of pandemic A(H1N1) influenzavirus/
cMRSA co-infection had infection with a cMRSA clone
containing the genes encoding PVL toxin (ST93-MRSA-IV). This
is consistent with recent data from our region suggesting that the
PVL is not essential for the development of severe cMRSA CAP
[42]. The patient with PVL-containing MRSA infection did,
however, have a severe and protracted pulmonary infection
consistent with necrotizing pneumonia that progressed despite
early therapy with the protein synthesis inhibitor clindamycin,
similar to the previous case report of pandemic A(H1N1)
influenzavirus co-infection which was caused by another PVL-
containing cMRSA clone (ST30-MRSA-IV)[41].
This study has several limitations. Firstly, it was performed in
only two adult tertiary hospitals in an isolated Australian city, so
the results may not be generalizable to the pediatric population or
to regions with differing cMRSA prevalence. Secondly, patients
with mild-to-moderate CAP (who often do not have microbiolog-
ical tests performed) were not represented, therefore the data may
overestimate the severity of co-infection. Finally, as we did not
perform immunohistochemical staining, we could not conclusively
demonstrate that MRSA was present in the two post-mortem lung
specimens, however, histopathological findings were suggestive of
an acute bacterial pneumonia, and cMRSA was the dominant
organism isolated on culture.
This report emphasizes the importance of bacterial co-infection
in pandemic A(H1N1)2009 influenzavirus infection. Clinicians
should be alert to the possibility of cMRSA co-infection in patients
with suspected influenza pneumonitis, should ensure that appro-
priate lower respiratory tract specimens are obtained for the
detection of influenzavirus and MRSA, and should consider
Table 2. MRSA typing results.
patient source antibiogram
lukS-PV/lukFP V
PCR PFGE designation MLST sequence
MLST sequence type
(clonal complex) spa type
SCCmec
type agr type
1 sputum S + Qld CA-MRSA 6-64-44-2-43-55-51 93 (singleton) t202 IVa III
1 blood S + Qld CA-MRSA 6-64-44-2-43-55-51 93 (singleton) t202 IVa III
2 sputum S 2 WA MRSA-1 1-1-1-1-1-1-1 1 (1) t177 IVa III
2 blood S 2 WA MRSA-1 1-1-1-1-1-1-1 1 (1) t177 IVa III
3 sputum S 2 WA MRSA-1 1-1-1-1-1-1-1 1 (1) t127 IVa III
3 blood S 2 WA MRSA-1 1-1-1-1-1-1-1 1 (1) t127 IVa III
4 lung Ery
R,I R C 2 WA MRSA-2 22-1-14-23-12-53-31 78 (88) t186 IVa III
5 lung Ery
R,I R C 2 WA MRSA-2 22-1-14-23-12-53-31 78 (88) t186 IVa III
Note: S=isolate tested susceptible to all non-beta lactam agents tested; Ery
R=erythromycin resistant; IRC=inducible resistance to clindamycin;lukS-PV/lukF-PV=genes
encoding Panton-Valentine Leukocidin; PFGE=pulsed-field gel electrophoresis; MLST=multilocus sequence typing; spa=staphylococcal protein A gene;
agr=accessory gene regulator.
doi:10.1371/journal.pone.0008705.t002
Figure 5. Pulsed-field gel electrophoresis of MRSA isolates (Sma1 macrorestriction).
doi:10.1371/journal.pone.0008705.g005
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MRSA in regions where cMRSA is prevalent.
Supporting Information
Table S1 Primers and probes included in the duplex real-time
RT-PCR assays.
Found at: doi:10.1371/journal.pone.0008705.s001 (0.05 MB
DOC)
Table S2 Complete results of DNA microarray experiments on
MRSA isolates from patients with community-acquired pneumo-
nia due to pandemic A(H1N1)2009/cMRSA co-infection.
Found at: doi:10.1371/journal.pone.0008705.s002 (0.42 MB
DOC)
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